CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 484 enrolled
Drug / intervention
CLS006 (Furosemide) Topical Gel +1 moredrug
Likely dose
CLS006 (Furosemide) Topical Gel; specific dose not statedAI-extracted
Key inclusion· 7
  • ✓Age 2 years or older
  • ✓1 to 6 clearly identifiable common warts on hands, feet, limbs, and/or trunk
  • ✓Each wart 3–10 mm in longest dimension at baseline
  • ✓Each wart present for at least 4 weeks at baseline
Key exclusion· 11
  • ✕Plantar, facial, subungual warts, or warts in regions of pre-existing inflammatory condition
  • ✕Salicylic acid, cantharidin, sinecatechins, or over-the-counter wart products in treatment area within 4 weeks of baseline
  • ✕Cryotherapy, laser, surgery, or mechanical destruction in treatment area within 8 weeks of baseline
  • ✕Immunotherapy, imiquimod, 5-fluorouracil, bleomycin, podophyllin, or other immune-stimulating wart treatments within 12 weeks of baseline

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02971891
NCT02971891Phase 3Completed
CompareCT.gov

A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

Maruho Co., Ltd.·interventional·Posted Nov 23, 2016·Updated Sep 14, 2023

In Brief

A Phase 3 clinical trial evaluating CLS006 (Furosemide) Topical Gel and Vehicle Topical Gel for Cutaneous Common Warts. Completed, enrolled 484 participants across 30 sites.

Detailed Summary

To evaluate the efficacy and safety of six (6) weeks of once daily application of Furosemide Topical Gel 0.125% (CLS006) compared to vehicle in subjects ≥ 2 years of age with nongenital cutaneous common warts (verruca vulgaris).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCutaneous Common Warts
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 23, 2016
Enrollment StartJan 1, 2017
Primary CompletionApr 16, 2018
Study CompletionJul 10, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.6 years ago

Interventions

CLS006 (Furosemide) Topical Geldrug

Vehicle Topical Geldrug